Jevtana (cabazitaxel) is a small molecule pharmaceutical. Cabazitaxel was first approved as Jevtana on 2010-06-17. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat castration-resistant prostatic neoplasms and prostatic neoplasms. The pharmaceutical is active against tubulin beta chain. Jevtana's patents are valid until 2030-10-27 (FDA).
|Indication||castration-resistant prostatic neoplasms, prostatic neoplasms|
|Drug Class||Antineoplastics, taxane derivatives|